At Janssen Biotech, we harness innovations in large-molecule and small-molecule compounds to create important new therapeutic options. Beyond innovative medicines, we are also committed to programs that ensure healthcare providers, caregivers, patients and advocates have access to the latest treatment information and support services.
Educational grants and fellowships are provided for specific educational purposes that benefit healthcare professionals and patients in the following therapeutic areas:
Immunology
- Gastroenterology: IBD- Crohn’s Disease and Ulcerative Colitis
- Dermatology: Psoriasis
- Rheumatology: Psoriatic Arthritis, Ankylosing Spondylitis, Juvenile idiopathic arthritis
Oncology
- Solid Tumors: Prostate, Bladder, and Non-small Cell lung Cancers
- Hematologic Malignancies
- B-Cell Malignancies
- Chimeric antigen receptor T-cell therapy
Janssen Therapeutics strives to be a leader in the field of Infectious Diseases and Vaccines by supporting relevant, innovative, and quality education that enhances the understanding of our areas of interest to fulfill our responsibility to healthcare providers and people who use our products and services.
Educational grants and fellowships are provided for specific educational purposes that benefit patients and healthcare professionals in the following areas:
- HIV/AIDS
- Respiratory Syncytial Virus (RSV)
- Vaccines
Janssen Scientific Affairs, LLC is committed to improving patient care in our disease states of interest through support of independent educational grants for activities targeting healthcare providers, fellows, and patients/caregivers.
Educational grants and fellowships are provided for specific educational purposes that benefit patients and healthcare professionals in the following therapeutic areas:
Cardiovascular
Currently Accepting
- Obesity and the use of NOACs
- Stroke prevention with NOACs
- Dual pathway inhibition antithrombotic therapy to reduce major adverse events in patients with CAD and/or PAD
- Identification and management of high risk medically ill patients of thromboprophylaxis during hospitalization and following discharge.
Metabolism
Currently Not Accepting
- Cardiovascular, Heart Failure and Renal Management in Type 2 Diabetes Mellitus with Moderate-to-Severe Renal Impairment
Neuroscience
Currently Not Accepting
- Schizophrenia
- Major Depressive Disorder (including Treatment Resistant Depression)
We are not accepting applications for general support of the following regularly scheduled activities:
- Professional Society annual meetings, special interest conferences, sponsored regional series, or other regularly scheduled Society- sponsored meetings
- Single- or half-day regional update conferences Disease state-specific educational activities held in conjunction with these regularly scheduled meetings may be considered.
© Janssen Scientific Affairs, LLC 2014. All rights reserved.
Your use of the information on this site is subject to the terms of our Legal Notice. Please see our Privacy Policy.
This site is published by Janssen Scientific Affairs, LLC which is solely responsible for its contents.This information is intended for the use of our customers and healthcare professionals in the United States only. Janssen Scientific Affairs, LLC recognizes that the Internet is a global communications medium; however, laws, regulatory requirements and medical practices for pharmaceutical products vary from country to country.
This page was last updated on: January 2020